Literature DB >> 30570135

Secretory immunoglobulin A induces human lung fibroblasts to produce inflammatory cytokines and undergo activation.

S Arakawa1,2, M Suzukawa1, K Watanabe1,2, K Kobayashi1,2, H Matsui1, H Nagai1, T Nagase2, K Ohta1.   

Abstract

Immunoglobulin (Ig)A is the most abundant immunoglobulin in humans, and in the airway mucosa secretory IgA (sIgA) plays a pivotal role in first-line defense against invading pathogens and antigens. IgA has been reported to also have pathogenic effects, including possible worsening of the prognosis of idiopathic pulmonary fibrosis (IPF). However, the precise effects of IgA on lung fibroblasts remain unclear, and we aimed to elucidate how IgA activates human lung fibroblasts. We found that sIgA, but not monomeric IgA (mIgA), induced interleukin (IL)-6, IL-8, monocyte chemoattractant protein (MCP)-1 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production by normal human lung fibroblasts (NHLFs) at both the protein and mRNA levels. sIgA also promoted proliferation of NHLFs and collagen gel contraction comparable to with transforming growth factor (TGF)-β, which is involved in fibrogenesis in IPF. Also, Western blot analysis and real-time quantitative polymerase chain reaction (PCR) revealed that sIgA enhanced production of α-smooth muscle actin (α-SMA) and collagen type I (Col I) by NHLFs. Flow cytometry showed that NHLFs bound sIgA, and among the known IgA receptors, NHLFs significantly expressed CD71 (transferrin receptor). Transfection of siRNA targeting CD71 partially but significantly suppressed cytokine production by NHLFs co-cultured with sIgA. Our findings suggest that sIgA may promote human lung inflammation and fibrosis by enhancing production of inflammatory or fibrogenic cytokines as well as extracellular matrix, inducing fibroblast differentiation into myofibroblasts and promoting human lung fibroblast proliferation. sIgA's enhancement of cytokine production may be due partially to its binding to CD71 or the secretory component.
© 2018 British Society for Immunology.

Entities:  

Keywords:  IgA; fibroblasts; fibrosis; human; lung

Mesh:

Substances:

Year:  2019        PMID: 30570135      PMCID: PMC6378381          DOI: 10.1111/cei.13253

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Enhanced Anti-Cancer Effects of Conditioned Medium from Hypoxic Human Adult Dermal Fibroblasts on Cervical Cancer Cells.

Authors:  Kyu-Hyun Han; Ae-Kyeong Kim; Dong-Ik Kim
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

2.  Identification of ANXA2 on epithelial cells as a new receptor for secretory IgA using immunoprecipitation and mass spectrometry.

Authors:  Shizuka Watanabe; Koichi Kobayashi; Maho Suzukawa; Sayaka Igarashi; Kazufumi Takada; Sahoko Imoto; Masashi Kitani; Takeshi Fukami; Takahide Nagase; Ken Ohta
Journal:  Clin Exp Immunol       Date:  2022-06-23       Impact factor: 5.732

3.  Secretory IgA accumulated in the airspaces of idiopathic pulmonary fibrosis and promoted VEGF, TGF-β and IL-8 production by A549 cells.

Authors:  K Kobayashi; M Suzukawa; K Watanabe; S Arakawa; S Igarashi; I Asari; A Hebisawa; H Matsui; H Nagai; T Nagase; K Ohta
Journal:  Clin Exp Immunol       Date:  2019-11-08       Impact factor: 4.330

4.  Serum levels of the IgA isotype switch factor TGF-β1 are elevated in patients with COVID-19.

Authors:  Er-Yi Wang; Hao Chen; Bao-Qing Sun; Hui Wang; Hui-Qi Qu; Yichuan Liu; Xi-Zhuo Sun; Jingchun Qu; Zhang-Fu Fang; Lifeng Tian; Yi-Feng Zeng; Shau-Ku Huang; Hakon Hakonarson; Zhi-Gang Liu
Journal:  FEBS Lett       Date:  2021-05-21       Impact factor: 3.864

Review 5.  Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.

Authors:  Norma A Valdez-Cruz; Enrique García-Hernández; Clara Espitia; Laura Cobos-Marín; Claudia Altamirano; Carlos G Bando-Campos; Luis F Cofas-Vargas; Enrique W Coronado-Aceves; Ricardo A González-Hernández; Pablo Hernández-Peralta; Daniel Juárez-López; Paola A Ortega-Portilla; Sara Restrepo-Pineda; Patricio Zelada-Cordero; Mauricio A Trujillo-Roldán
Journal:  Microb Cell Fact       Date:  2021-04-22       Impact factor: 5.328

6.  Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.

Authors:  Maciej Tarkowski; Wilco de Jager; Marco Schiuma; Alice Covizzi; Alessia Lai; Arianna Gabrieli; Mario Corbellino; Annalisa Bergna; Carla Della Ventura; Massimo Galli; Agostino Riva; Spinello Antinori
Journal:  Front Immunol       Date:  2021-12-17       Impact factor: 7.561

Review 7.  Humoral immune mechanisms involved in protective and pathological immunity during COVID-19.

Authors:  Gunawan Widjaja; Abduladheem Turki Jalil; Heshu Sulaiman Rahman; Walid Kamal Abdelbasset; Dmitry O Bokov; Wanich Suksatan; Mahnaz Ghaebi; Faroogh Marofi; Jamshid Gholizadeh Navashenaq; Farhad Jadidi-Niaragh; Majid Ahmadi
Journal:  Hum Immunol       Date:  2021-07-01       Impact factor: 2.850

8.  Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.

Authors:  Hai-Qiong Yu; Bao-Qing Sun; Zhang-Fu Fang; Jin-Cun Zhao; Xiao-Yu Liu; Yi-Min Li; Xi-Zhuo Sun; Hong-Feng Liang; Bei Zhong; Zhi-Feng Huang; Pei-Yan Zheng; Li-Feng Tian; Hui-Qi Qu; De-Chen Liu; Er-Yi Wang; Xiao-Jun Xiao; Shi-Yue Li; Feng Ye; Li Guan; Dong-Sheng Hu; Hakon Hakonarson; Zhi-Gang Liu; Nan-Shan Zhong
Journal:  Eur Respir J       Date:  2020-08-27       Impact factor: 16.671

9.  Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis.

Authors:  Peter Heukels; Jennifer A C van Hulst; Menno van Nimwegen; Carian E Boorsma; Barbro N Melgert; Jan H von der Thusen; Bernt van den Blink; Rogier A S Hoek; Jelle R Miedema; Stefan F H Neys; Odilia B J Corneth; Rudi W Hendriks; Marlies S Wijsenbeek; Mirjam Kool
Journal:  Respir Res       Date:  2019-10-24

10.  Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?

Authors:  Alberto Beretta; Martin Cranage; Donato Zipeto
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.